

*Figures 1A - 1B*

FPF=95%

MMAD=2.8 $\mu$ m








Figure 2




*Figure 3*







*Figure 4*




**Figures 5A - 5B**



*Figures 6A - 6B*




*Figures 7A - 7D*





*Figure 8*









*Figure 9*



*Figures 10A - 10B*




*Figures 11A - 11C*




*Figure 12*

**A. Activation of TcH by HA 110-120 integrated in Ig, in context of B lymphoma APC**




**B. *In vitro* stimulation of TcH by IgHA in context of B lymphoma APC (18 hours incubation)**




**Figures 13A - 13B**


**A. InsB /  $\alpha$ -CD3 stimulated splenocytes**






**B. GAD/ anti-CD3 stimulated splenocytes**





**C. Peptide-stimulated splenocytes**



**Figures 14A - 14C**



*Figures 15A - 15C*



**Figures 16A - 16B**








Figure 17




### A. Th profile in MALT



### B. Th profile in spleen




Figures 18A - 18B




*Figures 19A - 19C*



### A. Kinetics of disease (adm. 8-10w)





### B. Kinetics of disease (8-20w)




Figures 20A - 20B



**Figures 21A - 21B**



*Figures 22A - 22B*



*Figures 23A - 23B*






Figure 24





*Figure 25*



*Figure 26*




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31